JOAQUIN SARMIENTO via Getty Images
Immunosuppressed subjects, transplant recipients, the elderly, guests of RSAs and health professionals at greater risk (for example if they are active in Covid departments). According to what has been learned, these are the categories for which the Technical Scientific Commission (Cts) of the Italian Medicines Agency (Aifa) has given the green light to the third dose of anti-Covid vaccination. For the boosters, according to the indications of the opinion of the Cts Aifa, the mRna vaccines will be used, namely the Pfizer and Moderna vaccines.
The third dose should be administered, according to what is learned, “at least after 28 days” from the second dose for immunosuppressed and transplant recipients. The recall should instead be made “at least after six months” for the other categories indicated, that is the elderly, guests of the Rsa and health personnel at risk. This would be the indication contained in the opinion on the third dose prepared by the Scientific Technical Commission (Cts) of the Italian Medicines Agency (Aifa).
The general population is not included in the opinion of the AIFA Commission, because further data are expected for the evaluation of the recall on the wider population. To specify it is the same Aifa. In the provision, he explains, “the general population is not included pending EMA to evaluate the data provided by the manufacturers of the aforementioned vaccines”. “The extension of this measure to the national level, taken in advance of the EMA position, is configured as an important public health act for the protection of the population most exposed to severe forms of Covid”.
“We are ready. By September we will be leaving with this recall. The doses are there, we have more than enough ”, said General Francesco Paolo Figliuolo, commissioner for the Covid emergency, at the end of the visit to the Piacenza hospital. “Scientists speak of a booster with RMNA vaccines, then Pfizer and Moderna. At a technical level we are already moving, we are finalizing the last details on the information systems, then we will give the indications to the Regions and the Autonomous Provinces and we will leave ”. The indications of the CTS are awaited to see to make a third dose also to the elderly and to those on the front line in the battle against Covid.
The opinion of the European Medicines Agency (EMA) is also expected in the coming days, which last week started the evaluation of the application submitted by Pfizer-BioNtech.